165 related articles for article (PubMed ID: 3972969)
1. RU486, a progestin and glucocorticoid antagonist, inhibits the growth of breast cancer cells via the progesterone receptor.
Bardon S; Vignon F; Chalbos D; Rochefort H
J Clin Endocrinol Metab; 1985 Apr; 60(4):692-7. PubMed ID: 3972969
[TBL] [Abstract][Full Text] [Related]
2. Growth stimulation of T47D human breast cancer cells by the anti-progestin RU486.
Bowden RT; Hissom JR; Moore MR
Endocrinology; 1989 May; 124(5):2642-4. PubMed ID: 2707170
[TBL] [Abstract][Full Text] [Related]
3. RU486, a progestin antagonist, binds to progesterone receptors in a human endometrial cancer cell line and reverses the growth inhibition by progestins.
Terakawa N; Shimizu I; Tanizawa O; Matsumoto K
J Steroid Biochem; 1988 Aug; 31(2):161-6. PubMed ID: 2457133
[TBL] [Abstract][Full Text] [Related]
4. Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells.
Gill PG; Vignon F; Bardon S; Derocq D; Rochefort H
Breast Cancer Res Treat; 1987 Oct; 10(1):37-45. PubMed ID: 3689980
[TBL] [Abstract][Full Text] [Related]
5. The antiprogestin RU38 486: receptor-mediated progestin versus antiprogestin actions screened in estrogen-insensitive T47Dco human breast cancer cells.
Horwitz KB
Endocrinology; 1985 Jun; 116(6):2236-45. PubMed ID: 4039656
[TBL] [Abstract][Full Text] [Related]
6. Effects of progestins, estrogens, and antihormones on growth and lactate dehydrogenase in the human breast cancer cell line T47D.
Hissom JR; Bowden RT; Moore MR
Endocrinology; 1989 Jul; 125(1):418-23. PubMed ID: 2737155
[TBL] [Abstract][Full Text] [Related]
7. The anti-progestin RU486 stabilizes the progestin-induced fatty acid synthetase mRNA but does not stimulate its transcription.
Chalbos D; Galtier F; Emiliani S; Rochefort H
J Biol Chem; 1991 May; 266(13):8220-4. PubMed ID: 2022639
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogenic effect of R5020, a synthetic progestin in human breast cancer cells in culture.
Vignon F; Bardon S; Chalbos D; Rochefort H
J Clin Endocrinol Metab; 1983 Jun; 56(6):1124-30. PubMed ID: 6682424
[TBL] [Abstract][Full Text] [Related]
9. Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture.
Gompel A; Malet C; Spritzer P; Lalardrie JP; Kuttenn F; Mauvais-Jarvis P
J Clin Endocrinol Metab; 1986 Nov; 63(5):1174-80. PubMed ID: 2428825
[TBL] [Abstract][Full Text] [Related]
10. Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells.
Bardon S; Vignon F; Montcourrier P; Rochefort H
Cancer Res; 1987 Mar; 47(5):1441-8. PubMed ID: 3815345
[TBL] [Abstract][Full Text] [Related]
11. Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines.
Ewing TM; Murphy LJ; Ng ML; Pang GY; Lee CS; Watts CK; Sutherland RL
Int J Cancer; 1989 Oct; 44(4):744-52. PubMed ID: 2793247
[TBL] [Abstract][Full Text] [Related]
12. Progesterone agonists and antagonists induce down- and up-regulation of estrogen receptors and estrogen inducible genes in human breast cancer cell lines.
Savoldi G; Ferrari F; Ruggeri G; Sobek L; Albertini A; Di Lorenzo D
Int J Biol Markers; 1995; 10(1):47-54. PubMed ID: 7629427
[TBL] [Abstract][Full Text] [Related]
13. Immunocytochemical localization of progesterone receptors in breast cancer with anti-human receptor monoclonal antibodies.
Elashry-Stowers D; Zava DT; Speers WC; Edwards DP
Cancer Res; 1988 Nov; 48(22):6462-74. PubMed ID: 3180062
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47DCO human breast cancer cells by progestins: implications for endocrine therapies.
Horwitz KB; Freidenberg GR
Cancer Res; 1985 Jan; 45(1):167-73. PubMed ID: 3838085
[TBL] [Abstract][Full Text] [Related]
15. Effect of progestin treatment on estradiol-and growth factor-stimulated breast cancer cell lines.
Cappelletti V; Miodini P; Fioravanti L; Di Fronzo G
Anticancer Res; 1995; 15(6B):2551-5. PubMed ID: 8669822
[TBL] [Abstract][Full Text] [Related]
16. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells.
Le Bihan S; Marsaud V; Mercier-Bodard C; Baulieu EE; Mader S; White JH; Renoir JM
Mol Endocrinol; 1998 Jul; 12(7):986-1001. PubMed ID: 9658403
[TBL] [Abstract][Full Text] [Related]
17. A 250-kilodalton cellular protein is induced by progestins in two human breast cancer cell lines MCF7 and T47D.
Chalbos D; Rochefort H
Biochem Biophys Res Commun; 1984 Jun; 121(2):421-7. PubMed ID: 6539596
[TBL] [Abstract][Full Text] [Related]
18. The steroid antagonist RU486 exerts different effects on the glucocorticoid and progesterone receptors.
Beck CA; Estes PA; Bona BJ; Muro-Cacho CA; Nordeen SK; Edwards DP
Endocrinology; 1993 Aug; 133(2):728-40. PubMed ID: 8344212
[TBL] [Abstract][Full Text] [Related]
19. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
20. Progestins and androgens stimulate lipid accumulation in T47D breast cancer cells via their own receptors.
Chambon M; Rochefort H; Vial HJ; Chalbos D
J Steroid Biochem; 1989 Nov; 33(5):915-22. PubMed ID: 2601336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
